PLIANT THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable
PLIANT THERAPEUTICS, INC. (PLRX) reported Increase (Decrease) in Accounts Payable of $1.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-11
- PLIANT THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $1.17M.
- PLIANT THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$118.00K.
- PLIANT THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$3.00K.
- PLIANT THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$897.00K, a 124.07% decline year-over-year.
- PLIANT THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2025 was -$5.48M, a 483.75% decline from fiscal 2024.
- PLIANT THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2024 was $1.43M, a 51.90% decline from fiscal 2023.
- PLIANT THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2023 was $2.97M.
- PLIANT THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2022 was -$1.35M, a 251.63% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.05M 10-Q · filed 2026-08-11 | $1.05M derived: sum of 3 quarters · filed 2026-08-11 | $151.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$118.00K 10-Q · filed 2026-05-11 | -$121.00K derived: sum of 2 quarters · filed 2026-05-11 | -$1.02M derived: sum of 3 quarters · filed 2026-05-11 | -$5.26M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$900.00K derived: sum of 2 quarters · filed 2026-03-11 | -$5.14M derived: sum of 3 quarters · filed 2026-08-11 | -$5.48M 10-K · filed 2026-03-11 |
| 2025-09-30 | -$897.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$5.14M derived: sum of 2 quarters · filed 2026-08-11 | -$5.48M 10-Q · filed 2025-11-06 | -$6.41M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$4.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$4.58M 10-Q · filed 2026-08-11 | -$5.51M derived: sum of 3 quarters · filed 2026-08-11 | -$1.78M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$338.00K 10-Q · filed 2026-05-11 | -$1.27M derived: sum of 2 quarters · filed 2026-05-11 | $2.46M derived: sum of 3 quarters · filed 2026-05-11 | -$1.17M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$930.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $2.80M derived: sum of 2 quarters · filed 2026-03-11 | -$829.00K derived: sum of 3 quarters · filed 2026-03-11 | $1.43M 10-K · filed 2026-03-11 |
| 2024-09-30 | $3.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $101.00K derived: sum of 2 quarters · filed 2025-11-06 | $2.36M 10-Q · filed 2025-11-06 | $3.53M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$3.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.37M 10-Q · filed 2025-08-07 | -$197.00K derived: sum of 3 quarters · filed 2025-08-07 | $862.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $2.26M 10-Q · filed 2025-05-08 | $3.43M derived: sum of 2 quarters · filed 2025-05-08 | $4.49M derived: sum of 3 quarters · filed 2025-05-08 | $5.37M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $2.23M derived: sum of 2 quarters · filed 2025-03-03 | $3.11M derived: sum of 3 quarters · filed 2025-03-03 | $2.97M 10-K · filed 2025-03-03 |
| 2023-09-30 | $1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.94M derived: sum of 2 quarters · filed 2024-11-07 | $1.80M 10-Q · filed 2024-11-07 | $192.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $882.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $738.00K 10-Q · filed 2024-08-07 | -$867.00K derived: sum of 3 quarters · filed 2025-03-03 | -$815.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$144.00K 10-Q · filed 2024-05-06 | -$1.75M derived: sum of 2 quarters · filed 2025-03-03 | -$1.70M derived: sum of 3 quarters · filed 2025-03-03 | -$3.27M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$1.55M derived: sum of 2 quarters · filed 2025-03-03 | -$3.12M derived: sum of 3 quarters · filed 2025-03-03 | -$1.35M 10-K · filed 2025-03-03 |
| 2022-09-30 | $52.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$1.52M derived: sum of 2 quarters · filed 2023-11-09 | $254.00K 10-Q · filed 2023-11-09 | $744.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $202.00K 10-Q · filed 2023-08-09 | $692.00K derived: sum of 3 quarters · filed 2024-02-27 | $352.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $1.77M 10-Q · filed 2023-05-09 | $2.26M derived: sum of 2 quarters · filed 2024-02-27 | $1.92M derived: sum of 3 quarters · filed 2024-02-27 | $2.00M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $490.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $150.00K derived: sum of 2 quarters · filed 2024-02-27 | $226.00K derived: sum of 3 quarters · filed 2024-02-27 | $891.00K 10-K · filed 2024-02-27 |
| 2021-09-30 | -$340.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$264.00K derived: sum of 2 quarters · filed 2022-11-08 | $401.00K 10-Q · filed 2022-11-08 | -$503.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $76.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $741.00K 10-Q · filed 2022-08-08 | -$163.00K derived: sum of 3 quarters · filed 2022-08-08 | $988.00K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $665.00K 10-Q · filed 2022-05-09 | -$239.00K derived: sum of 2 quarters · filed 2022-05-09 | $912.00K derived: sum of 3 quarters · filed 2022-05-09 | $411.00K derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$904.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $247.00K derived: sum of 2 quarters · filed 2022-03-01 | -$254.00K derived: sum of 3 quarters · filed 2022-03-01 | $922.00K 10-K · filed 2022-03-01 |
| 2020-09-30 | $1.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $650.00K derived: sum of 2 quarters · filed 2021-11-09 | $1.83M 10-Q · filed 2021-11-09 | $359.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$501.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $675.00K 10-Q · filed 2021-08-09 | -$792.00K derived: sum of 3 quarters · filed 2022-03-01 | -$2.40M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $1.18M 10-Q · filed 2021-05-10 | -$291.00K derived: sum of 2 quarters · filed 2022-03-01 | -$1.89M derived: sum of 3 quarters · filed 2022-03-01 | |
| 2019-12-31 | -$1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$3.07M derived: sum of 2 quarters · filed 2022-03-01 | -$1.25M 10-K · filed 2022-03-01 | |
| 2019-09-30 | -$1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $212.00K 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $1.81M 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |